175 related articles for article (PubMed ID: 38427775)
1. Smoldering multiple myeloma: taking the narrow over the wide path?
Avet-Loiseau H; Bahlis NJ
Blood; 2024 May; 143(20):2025-2028. PubMed ID: 38427775
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
[TBL] [Abstract][Full Text] [Related]
3. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Kunacheewa C; Manasanch EE
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
[TBL] [Abstract][Full Text] [Related]
4. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
5. Smoldering multiple myeloma: biology, clinical manifestations and management.
Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
[TBL] [Abstract][Full Text] [Related]
6. Smoldering multiple myeloma: Reviewing the rationale for intervention.
Gertz M
Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
[TBL] [Abstract][Full Text] [Related]
7. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
8. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
9. Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
[TBL] [Abstract][Full Text] [Related]
10. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
[TBL] [Abstract][Full Text] [Related]
11. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
Rajkumar SV; Bergsagel PL; Kumar S
Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
13. Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Maclachlan KH; Lesokhin AM
Cancer Cell; 2022 Nov; 40(11):1270-1272. PubMed ID: 36379204
[TBL] [Abstract][Full Text] [Related]
14. Smoldering multiple myeloma 40 years later: a story of unintended disease.
Yavorkovsky LL
Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
[No Abstract] [Full Text] [Related]
15. The consultant's guide to smoldering multiple myeloma.
Thorsteinsdottir S; Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
[TBL] [Abstract][Full Text] [Related]
16. High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
Fernandez N; Perumal D; Rahman A; Kim-Schulze S; Yesil J; Auclair D; Adams H; Parekh S; Gnjatic S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):853-862. PubMed ID: 35945129
[TBL] [Abstract][Full Text] [Related]
17. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
19. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
20. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
